![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TC Chambers, B Zheng and JF Kuo
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322.
Covalent modification by phosphorylation is a characteristic of the P- glycoproteins expressed in multidrug-resistant cells. This report describes analysis of P-glycoprotein phosphorylation in multidrug- resistant human KB-V1 cells and a study of the relationship of phosphorylation and drug accumulation. In isolated membranes, phosphorylation of P-glycoprotein by purified protein kinase C (PKC) was rapid, and time-dependent dephosphorylation was inhibited by okadaic acid, an inhibitor of type 1 and type 2A protein phosphatases. In 32P-labeled intact KB-V1 cells, P-glycoprotein phosphorylation was stimulated by both 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of PKC, and okadaic acid. Two-dimensional thin layer tryptic phosphopeptide maps indicated that the sites of phosphorylation were similar in control, TPA-treated, and okadaic acid-treated cells and that they corresponded to those phosphorylated by PKC in vitro. The protein kinase inhibitor staurosporine, and the PKC-selective inhibitors calphostin C and the alkyl-lysophospholipid 1-O-octadecyl-2- O-methyl-rac-glycero-3-phosphocholine, inhibited P-glycoprotein phosphorylation in vitro and in intact cells. Drug accumulation assays demonstrated that in KB-V1 cells TPA caused a decrease, whereas staurosporine and calphostin C caused an increase, in accumulation of [3H]vinblastine. These compounds did not significantly alter [3H]vinblastine levels in drug-sensitive KB-3 cells. These results suggest that PKC is chiefly responsible for P-glycoprotein phosphorylation in KB-V1 cells, that membrane-associated protein phosphatases 1 and 2A are active in dephosphorylation of P- glycoprotein, and that phosphorylation of P-glycoprotein may be an important mechanism for modulation of drug-pumping activity.
This article has been cited by other articles:
|
|
 |
|
  C. H. Seedhouse, M. Grundy, P. White, Y. Li, J. Fisher, D. Yakunina, A. V. Moorman, T. Hoy, N. Russell, A. Burnett, et al. Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials Clin. Cancer Res., December 1, 2007; 13(23): 7059 - 7066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-i. Wada, M. Niimi, K. Niimi, A. R. Holmes, B. C. Monk, R. D. Cannon, and Y. Uehara Candida glabrata ATP-binding Cassette Transporters Cdr1p and Pdh1p Expressed in a Saccharomyces cerevisiae Strain Deficient in Membrane Transporters Show Phosphorylation-dependent Pumping Properties J. Biol. Chem., November 22, 2002; 277(48): 46809 - 46821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lee, S. Dallas, M. Hong, and R. Bendayan Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations Pharmacol. Rev., December 1, 2001; 53(4): 569 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Decottignies, G. Owsianik, and M. Ghislain Casein Kinase I-dependent Phosphorylation and Stability of the Yeast Multidrug Transporter Pdr5p J. Biol. Chem., December 24, 1999; 274(52): 37139 - 37146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Szabo, E. Bakos, E. Welker, M. Muller, H. R. Goodfellow, C. F. Higgins, A. Varadi, and B. Sarkadi Phosphorylation Site Mutations in the Human Multidrug Transporter Modulate Its Drug-stimulated ATPase Activity J. Biol. Chem., September 12, 1997; 272(37): 23165 - 23171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Hemenway and J. Heitman Immunosuppressant Target Protein FKBP12 Is Required for P-Glycoprotein Function in Yeast J. Biol. Chem., August 2, 1996; 271(31): 18527 - 18534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Fine, T. C. Chambers, and C. W. Sachs P-Glycoprotein, Multidrug Resistance and Protein Kinase C Oncologist, August 1, 1996; 1(4): 261 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Goodfellow, A. Sardini, S. Ruetz, R. Callaghan, P. Gros, P. A. McNaughton, and C. F. Higgins Protein Kinase C-mediated Phosphorylation Does Not Regulate Drug Transport by the Human Multidrug Resistance P-glycoprotein J. Biol. Chem., June 7, 1996; 271(23): 13668 - 13674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Gupta, N. E. Ward, K. R. Gravitt, P. J. Bergman, and C. A. O'Brian Partial Reversal of Multidrug Resistance in Human Breast Cancer Cells by an N-Myristoylated Protein Kinase C-alpha Pseudosubstrate Peptide J. Biol. Chem., January 26, 1996; 271(4): 2102 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. A. Germann, T. C. Chambers, S. V. Ambudkar, T. Licht, C. O. Cardarelli, I. Pastan, and M. M. Gottesman Characterization of Phosphorylation-defective Mutants of Human P-glycoprotein Expressed in Mammalian Cells J. Biol. Chem., January 19, 1996; 271(3): 1708 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Fine, T. Chambers, and C. Sachs P-glycoprotein, multidrug resistance and protein kinase C Stem Cells, January 1, 1996; 14(1): 47 - 55. [Abstract]
|
|
|
|
|
|
C. W. Sachs, A. R. Safa, S. D. Harrison, and R. L. Fine Partial Inhibition of Multidrug Resistance by Safingol Is Independent of Modulation of P-glycoprotein Substrate Activities and Correlated with Inhibition of Protein Kinase C J. Biol. Chem., November 3, 1995; 270(44): 26639 - 26648. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
